Suppola J P, Volin L, Valtonen V V, Vaara M
Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Finland.
Clin Infect Dis. 1996 Oct;23(4):694-7. doi: 10.1093/clinids/23.4.694.
The objective of this study was to characterize the overgrowth and susceptibility of Enterococcus faecium, compared with that of other enterococci, in the feces of patients with hematologic malignancy. During a 52-week period, surveillance samples of feces were cultured weekly. Three hundred thirty-three samples were obtained from 92 patients. E. faecium outnumbered other enterococci in 170 (44%) of the samples, while the opposite was true in 119 (31%) of the samples. Fecal overgrowth of E. faecium (> or = 9.0 log10 cfu/g) was found in 62 samples (16%), while overgrowth of other enterococci was documented in 20 samples (5%) (P < .001). Treatment with third-generation cephalosporins preceded the overgrowth of E. faecium in 93% of the patients. Resistance of E. faecium isolates to ampicillin, high-level gentamicin, and vancomycin was detected in 41%, 4%, and 2% of the patients, respectively. There were 6 patients with enterococcal bacteremia (due to E. faecium in 5 and Enterococcus faecalis in 1) during the study period. The high prevalence of resistance to ampicillin and imipenem rendered few (if any) intravenous antibiotics able to prevent fecal overgrowth of E. faecium.
本研究的目的是比较粪肠球菌与其他肠球菌在血液系统恶性肿瘤患者粪便中的过度生长情况和易感性。在52周的时间里,每周对粪便监测样本进行培养。从92例患者中获取了333份样本。在170份(44%)样本中,粪肠球菌数量超过其他肠球菌,而在119份(31%)样本中情况则相反。在62份样本(16%)中发现粪肠球菌在粪便中过度生长(≥9.0 log10 cfu/g),而在20份样本(5%)中记录到其他肠球菌过度生长(P <.001)。93%的患者在粪肠球菌过度生长之前接受了第三代头孢菌素治疗。粪肠球菌分离株对氨苄西林、高水平庆大霉素和万古霉素的耐药率分别在41%、4%和2%的患者中检测到。在研究期间有6例患者发生肠球菌血症(5例由粪肠球菌引起,1例由粪肠球菌引起)。对氨苄西林和亚胺培南的高耐药率使得几乎没有(如果有的话)静脉用抗生素能够预防粪肠球菌在粪便中的过度生长。